RecruitingRecruiting
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
NCT07866066 · Amgen
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 3, Randomized, Open-Label Trial Comparing the Efficacy and Safety of Maridebart Cafraglutide Once Monthly Versus Semaglutide Once Weekly as Add-on Therapy to Metformin With or Without a Sodium-glucose Cotransporter-2 Inhibitor in Participants With Type 2 Diabetes
About this study
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Eligibility criteria
Inclusion Criteria:
* HbA1c of ≥ 7.5% (58.0 millimoles per mole (mmol/mol)) and ≤ 10.5% (91.0 mmol/mol) at screening.
* Treatment of Type 2 diabetes (T2D) with metformin (≥ 1500 milligrams per day (mg/day), or maximum tolerated dose as per investigator judgment) with or without an sodium-glucose cotransporter-2 (SGLT-2) inhibitor on a stable total daily dose for at least 90 days prior to randomization.
* Body mass index (BMI) ≥ 25 kilograms per meter squared (kg/m\^2) at screening.
Exclusion Criteria:
* Type 1 diabetes mellitus (T1DM), history of ketoacidosis or hyperosmolar state/coma, or any other type of diabetes mellitus except T2D or past history of gestational diabetes.
* Participants who are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.
* Participants who have a diagnosis of proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy.
* One or more episode of severe hypoglycemia (Level 3 hypoglycemia) within 180 days before screening, as defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery.
* History of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.
* Self-reported change in body weight \> 5% within 90 days before screening. Participants must also agree to not initiate an intensive diet or exercise program during the trial with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.
* Previous or planned (during the trial) surgical, endoscopic, or device-based treatment for obesity. The following are allowed:
* liposuction and/or abdominoplasty that was performed \> 1 year before screening.
* laparoscopic adjustable gastric banding, intragastric balloon, and/or duodenal-jejunal bypass liner or gastric sleeve if removed \> 1 year before screening.
Study design
Enrollment target: 1300 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-10-16
Estimated completion: 2028-12-05
Last updated: 2026-11-05
Interventions
Drug: Maridebart cafraglutideDrug: Semaglutide
Primary outcomes
- • Change from Baseline in Hemoglobin A1c (HbA1c) at Week 68 [Non-inferiority] (Baseline to Week 68)
Sponsor
Amgen · industry
Contacts & investigators
ContactAmgen Call Center · contact · medinfo@amgen.com · 866-572-6436
InvestigatorMD · study_director, Amgen
All locations (8)
Acclaim Clinical ResearchRecruiting
San Diego, California, United States
Bioclinical Research AllianceRecruiting
Miami, Florida, United States
Indago Research and Health CenterRecruiting
Miami Lakes, Florida, United States
Clinical Research Center Of FloridaRecruiting
Pompano Beach, Florida, United States
Conquest Research - Winter ParkRecruiting
Winter Park, Florida, United States
Virginia Nephrology GroupRecruiting
Arlington, Virginia, United States
Eastside Research Associates Health ResearchRecruiting
Redmond, Washington, United States
Dr T G Elliott Incorporated - BC DiabetesRecruiting
Vancouver, British Columbia, Canada